Variety of eligible clients: CDEC discussed the uncertainty in the quantity of patients with moderately critical to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some sufferers who will be labeled as obtaining moderate or average sickness could possibly have a severe bleed